Imugene Limited (ASX: IMU), a prominent player in the immuno-oncology field, has released an encouraging update on its Phase 1 MAST trial, which evaluates the safety and efficacy of the novel oncolytic virus, CF33-hNIS (VAXINIA), used both as monotherapy and in combination with pembrolizumab (KEYTRUDA). As the trial progresses, noteworthy outcomes are emerging, particularly in the treatment of challenging bile duct cancers.

Groundbreaking Outcomes in Advanced Cancer Treatment

As of October 31, 2023, the MAST trial has reached significant milestones. A total of 34 patients with metastatic advanced solid tumours have been dosed with VAXINIA. Early results reveal a disease control rate of 75% in 6 patients with gastrointestinal cancers treated with CF33-hNIS alone. Among these, the standout data includes a patient with bile duct cancer achieving a Complete Response with no recurrence for over 200 days and another showing stable disease for more than four months.

Safety and Dose Escalation Success

The trial, which is set to span across multiple centers in the U.S. and Australia, commenced with low doses of VAXINIA. The promising early response data, particularly at the mid-dose level, signals VAXINIA as a potential potent anti-cancer drug. Importantly, no adverse safety signals have been observed, allowing researchers to explore higher dose levels confidently.

Ongoing Progress and Future Expansion

The trial aims to expand, planning to include 10 patients with bile duct cancers. Leslie Chong, the Managing Director and CEO of Imugene, expressed optimism about the trial’s direction, citing the mid-dose level’s positive data and the opportunity to investigate higher doses.

  Australia, bile duct cancer, CF33-hNIS, Imugene, Keytruda, pembrolizumab, VAXINIA